Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsCash from RestructuringChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuphoria Therapeutics (NEUP) Gains from Investment Securities (2023 - 2025)

Historic Gains from Investment Securities for Neuphoria Therapeutics (NEUP) over the last 3 years, with Q4 2025 value amounting to $136770.0.

  • Neuphoria Therapeutics' Gains from Investment Securities rose 16894.64% to $136770.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $136770.0, marking a year-over-year increase of 16894.64%. This contributed to the annual value of $91211.0 for FY2025, which is 10488.17% up from last year.
  • Neuphoria Therapeutics' Gains from Investment Securities amounted to $136770.0 in Q4 2025, which was up 16894.64% from $137027.0 recorded in Q3 2025.
  • Neuphoria Therapeutics' Gains from Investment Securities' 5-year high stood at $78.3 million during Q2 2023, with a 5-year trough of -$3.0 million in Q3 2024.
  • Over the past 3 years, Neuphoria Therapeutics' median Gains from Investment Securities value was $136770.0 (recorded in 2025), while the average stood at $11.1 million.
  • Examining YoY changes over the last 5 years, Neuphoria Therapeutics' Gains from Investment Securities showed a top increase of 16894.64% in 2025 and a maximum decrease of 10461.95% in 2025.
  • Neuphoria Therapeutics' Gains from Investment Securities (Quarter) stood at $78.3 million in 2023, then plummeted by 99.94% to $50854.0 in 2024, then soared by 168.95% to $136770.0 in 2025.
  • Its Gains from Investment Securities stands at $136770.0 for Q4 2025, versus $137027.0 for Q3 2025 and $1.8 million for Q2 2025.